Industry Experts

Joel Goldstein received his PhD in molecular biology from the University of Medicine and Dentistry of New Jersey in 1991. His postdoctoral work was done at Bristol-Myers Squibb on antibody fusion proteins prior to joining Medarex in 1994. At Medarex Joel’s role was initially to develop bispecific antibodies and antibody fusion proteins, and then to develop antibody production platforms for manufacture. Joel moved back to BMS in 2009 where he led a team developing manufacturing cell lines for the company’s biologics programs. He then joined Celldex Therapeutics in 2014 to help manage R&D efforts, including establishing antibody engineering and bispecific antibody design strategies for the company’s pipeline.